Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2463${count})

  • Community Fast Track, 2003
    Biomarker Discovery in Parkinson’s Disease

    The primary goal of our studies is to expand our ongoing biomarker discovery program in order to establish biological markers of Parkinson's disease (PD). The imperative to develop effective therapies...

  • Community Fast Track, 2003
    Mitochondrial Trafficking in Dopaminergic Neuron Injury

    Mitochondria are considered to be the "power house" of all cells, including neurons, because they convert food into energy in the form that cells can use. When mitochondria fail, cells typically die...

  • LEAPS, 2003
    High Resolution Whole Genome Study to Determine Genetic Loci of Parkinson's Disease

    The Cox team will leverage Perlegen's high-density array technology and the Mayo Clinic's extensive patient database, clinical expertise and DNA bank to create a genetic map of causes and risk factors...

  • Community Fast Track, 2003
    Regulation of Dopaminergic Pathways by Eph Family Receptors

    Replacing dopaminergic neurons is an attractive alternative in the treatment of Parkinson's disease (PD). However, a successful treatment relies not only on the introduction of new neurons, but also...

  • Community Fast Track, 2002
    Proactive action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a pre-clinical model model of Parkinson's disease

    Recently, in mouse studies the peroxisome proliferator-activated receptor-g (PPARg) agonist pioglitazone was shown to be effective in blocking the substantia nigra (SN) cell loss induced by MPTP in a...

  • Biomarkers, 2002
    Peripheral Benzodiazepine Receptor: An In Vivo Biomarker of Parkinson's Disease

    The goal of the proposed studies is to validate an early marker of Parkinson's disease (PD) that may be able to identify disease onset prior to clinical manifestation. It is now recognized that in PD...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.